Clover Health (CLOV) Q3 2026 Earnings Call Transcript
Clover Health (CLOV) reported Q3 2026 earnings, highlighting 49% YoY membership growth to 157,000 members, 57% revenue increase to $2.3B, and doubled adjusted EBITDA to $97M. The company achieved high Star Ratings for its plans and improved HEDIS quality performance. Clover Assistant's engagement accelerated, driving better care and economics. The board appointed Clay Thornton as permanent CFO. Management expects continued growth and profitability in 2027 and 2028.
How this was made
The 30-second read
Why it matters
The earnings beat and strong membership growth provide a catalyst for short‑term price appreciation, while the guidance outlook remains cautious.
Market read
First‑report earnings with sizable revenue growth, likely to move CLOV stock and influence health‑care sector sentiment.
What to watch
Potential regulatory changes to Star Ratings and Medicare Advantage reimbursement could affect long‑term margins.
Background
Clover Health, a Medicare Advantage insurer, held an earnings call for Q3 2026, presenting its financial and operational performance.
Ticker impact
Q3 2026 earnings released showing revenue up 57% to $2.3B and net income $62M, a material beat.
likely upward as investors price in accelerated revenue growth and profitability
Revenue and profit surged year‑over‑year, cash balance strong, no debt; market typically rewards such Medicare Advantage growth.
Market effects
Highlights strength in Medicare Advantage and health‑tech, may boost related insurers and AI‑driven health firms.
Positive for U.S. health‑care sector, especially providers with risk‑adjusted models.
Limited; primarily U.S. health‑care investors.
Counterpoint
Rapid membership growth could strain cost controls; future profitability may be challenged if enrollment slows.
Key entities
- companyClover Health
U.S. listed Medicare Advantage insurer (ticker CLOV).
- personClay Thornton
Appointed Chief Financial Officer during the call.
